The process of developing new medicines has always been painfully slow, taking years of research, billions of dollars in investment, and facing dauntingly high failure rates. But according to Demis Hassabis, Nobel Prize-winning CEO of DeepMind and Isomorphic Labs, artificial intelligence is about to rewrite that story—potentially reducing the drug discovery timeline from years to just months.
A Paradigm Shift in Medicine Through AI
In a recent interview with Bloomberg Television, Hassabis shared a bold vision for the future of pharmaceuticals.
“In the next couple of years, I’d like to see that cut down in a matter of months, instead of years,” Hassabis said. “That’s what I think is possible. Perhaps even faster.”
This statement comes as Google DeepMind—Alphabet’s AI powerhouse—continues to push the boundaries of what AI can achieve in healthcare. Its sister division, Isomorphic Labs, launched in 2021, is specifically focused on using AI to transform drug discovery. The company has already secured high-profile collaborations with Eli Lilly & Co. and Novartis AG, signaling industry-wide confidence in AI’s potential to reshape medical innovation.
From AlphaFold to Real-World Breakthroughs
Isomorphic Labs was born out of AlphaFold, DeepMind’s revolutionary AI system capable of predicting protein structures—a long-standing scientific challenge. Hassabis, along with colleague John Jumper, earned the 2024 Nobel Prize in Chemistry for this breakthrough, alongside a US-based professor.
Now, the team is developing a “much more advanced” version of AlphaFold, which goes beyond protein interactions to understand broader biological processes. Hassabis believes this next-generation model could be the key to unlocking treatments for some of the world’s most pressing health problems.
Turning Ambition Into Action
The promise of AI in drug discovery has long excited pharmaceutical and biotech industries, offering the potential to:
- Speed up patient access to lifesaving treatments.
- Slash research and development costs.
- Respond more quickly to global health crises.
Yet, one hurdle remains—no AI-designed drug has yet cleared clinical trials. Isomorphic Labs announced in January that it aimed to begin clinical trials of AI-developed drugs by the end of 2025, but as of September, Hassabis admitted it’s “a bit early to say” when that milestone will be reached. Still, he emphasized that the company has achieved its “first few proof points” in moving drugs toward trials.
Targeting Cancer and Immune Disorders
For now, Isomorphic Labs is channeling its efforts into discovering treatments for cancer and immune-related diseases. According to Rebecca Paul, the company’s director for medicinal drug design, these conditions present a clearer pathway for AI models to translate into real-world clinical solutions.
In her own Bloomberg Television interview, Paul expressed cautious optimism:
“AI-developed drugs will turn many cancers into a treatable chronic disease. It’s really difficult to put a time stamp on it. But we can start to think about how we can approach this problem now.”
Strategic Partnerships and Growth
Isomorphic Labs is not just innovating scientifically—it’s also growing rapidly as a business. Earlier this year, the company raised $600 million in funding, led by Thrive Capital, which fueled its ambitious vision. Hassabis has previously suggested that Isomorphic Labs has the potential to become a $100 billion company, given the scale of opportunity in drug discovery.
The firm’s collaboration with Novartis is already bearing fruit. Initially focused on three therapeutic targets, the partnership has expanded to six. “There’s really good progress,” Paul noted, though she stopped short of sharing specific details.
Outlook
The vision is clear: if AI can shorten the drug discovery timeline from a decade to just months, the implications for healthcare, patients, and global well-being are staggering. While challenges remain, the momentum behind DeepMind and Isomorphic Labs is undeniable.
Hassabis and his team stand at the frontier of a new era—one where diseases like cancer may one day be managed like chronic conditions, and where lifesaving drugs reach patients at unprecedented speed.
Read more: Google Launches Genkit Go 1.0: A Game-Changer for AI Development in Go
